TG Therapeutics (NASDAQ:TGTX – Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.02), FiscalAI reports. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The firm had revenue of $259.94 million for the quarter, compared to the consensus estimate of $245.47 million.
TG Therapeutics Price Performance
NASDAQ TGTX opened at $59.83 on Monday. The stock’s 50-day moving average price is $55.80 and its two-hundred day moving average price is $44.50. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The company has a market cap of $9.16 billion, a PE ratio of 21.84, a PEG ratio of 2.53 and a beta of 1.89. TG Therapeutics has a 1 year low of $26.76 and a 1 year high of $63.60.
Insider Buying and Selling
In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares in the company, valued at $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 8.87% of the company’s stock.
Analyst Upgrades and Downgrades
TGTX has been the subject of several recent research reports. Weiss Ratings raised shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday. B. Riley Financial lifted their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. HC Wainwright reaffirmed a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. Zacks Research upgraded TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $63.00.
Check Out Our Latest Stock Report on TG Therapeutics
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.
The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.
Featured Stories
- Five stocks we like better than TG Therapeutics
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
